Abstracts tagged "Qualitative Research"

Abstract Number: 1280 • ACR Convergence 2021
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
Rebecca Hall¹, Nicola Williamson¹, Melissa Barclay¹, Anna Roberts¹, Adam Gater¹, Chloe Tolley¹, Helena Bradley¹, Amy Ward¹, Patricia Delong², Elizabeth Hsia³, Qing Zuraw⁴, Zahi Touma⁵, Vibeke Strand⁶ and Pamela Berry², ¹Adelphi Values Ltd, Bollington, United Kingdom, ²Janssen Global Services, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen R&D, Wayne, PA, ⁵University of Toronto, Mississauga, ON, Canada, ⁶Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Lupus nephritis (LN) is an autoimmune disease characterized by inflammation of the kidneys, a severe manifestation of systemic lupus erythematosus (SLE) that occurs in…
Abstract Number: 1597 • ACR Convergence 2021
Arthritis Patient Perspectives on Virtual Care for People Living with Arthritis During the COVID-19 Pandemic and for the Future
Maya Joshi¹, Anita Chan¹, Adriana Lima², Kelly Lendvoy¹, Eric Sayre² and Cheryl Koehn¹, ¹Arthritis Consumer Experts, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Virtual Care (VC) is the delivery of health care services and information by electronic methods (video, smartphones, email, text) and may support arthritis patients…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 1599 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
Courtney Wells¹, Guadalupe Torres², William Nowell³, Shilpa Venkatachalam³, Laura Stradford⁴, Kelly Gavigan³, Barbara Boyd-Floering⁵, Maria I. Danila⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Patient Partner, Brooklyn Center, MN, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Whelton Virshup CreakyJoints Arthritis Clinic/ Global Healthy Living Foundation, Lake Worth, FL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Independent, San Diego, CA
Background/Purpose: The purpose of this qualitative study was to understand the concerns, behaviors, and experiences of adults with autoimmune rheumatic conditions, and to evaluate the…
Abstract Number: 0145 • ACR Convergence 2021
Rheumatology Provider Perspectives on Using Patient-Reported Outcomes in Clinical Care
Yomei Shaw¹, Neda Kortam², Adam Chalak², Yujia Li², Faith Reger², Vivek Nagaraja² and Dinesh Khanna², ¹University of Michigan, East Lansing, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Patient-reported outcomes (PROs) are surveys completed by patients to provide measurements of health, quality of life, symptoms, and functional status. PROs are useful for…
Abstract Number: 1634 • ACR Convergence 2021
Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives
Ashley Ciosek¹, Una Makris², Justin Kramer³, Tracey Wright⁴ and Nicole Bitencourt⁵, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX, ³Texas A&M University, College Station, ⁴UT Southwestern Medical Center, Children's Health, Texas Scottish Rite Hospital for Children, Plano, TX, ⁵Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Advances in treatment of juvenile-onset systemic lupus erythematosus have ensured increased survival such that long-term quality of life and disease management must be considered.…
Abstract Number: 0400 • ACR Convergence 2021
Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire
John Pauling¹, Lesley Ann Saketkoo², Dinesh Khanna³, Christopher Denton⁴, Tracy Frech⁵, Ariane Herrick⁶, Laura Hummers⁷, Ami Shah⁸ and Robyn Domsic⁹, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, ³University of Michigan, Ann Arbor, MI, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁵University of Utah, Salt Lake City, UT, ⁶University of Manchester, Salford, United Kingdom, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
Abstract Number: 1644 • ACR Convergence 2021
Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study
Aviya Lanis¹, Emilee Tu², Malki Peskin³, Maryann Melendez¹, Gabriel Tarshish⁴, Alisha Akinsete⁵, Alicia Hoffman¹, Kathleen Kenney-Riley⁶, Tamar Rubinstein⁷ and Dawn Wahezi¹, ¹Children's Hospital at Montefiore, Bronx, NY, ²Albert Einstein School of Medicine, Bronx, NY, ³Montefiore, Bronx, NY, ⁴Children's Hospital at Montefiore, New York, NY, ⁵Montefiore, Wayne, NJ, ⁶Mercy College, Dobbs Ferry, NY, ⁷Albert Einstein College of Medicine, White Plains, NY
Background/Purpose: Storytelling is a universal form of communication that allows expression of experiences. Narrative medicine can be described as a subset of storytelling in which…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 1605 • ACR Convergence 2020
Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
Criswell Lavery¹, Marianna Olave², Charles Leonard¹, Vincent Lo Re¹, Jonathan Kay³ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The market introduction of biosimilars has generated the need for novel biologic naming conventions, in part to support pharmacovigilance. We evaluated the familiarity of…
Abstract Number: 1619 • ACR Convergence 2020
Immunoglobulin G Subclass Ordering Patterns for IgG4-Related Disease at an Academic Medical Center
Lena Eder¹ and David Leverenz², ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, DURHAM, NC
Background/Purpose: We have noticed an increasing number of serum IgG4 levels ordered over the last several years at our institution. This study was performed to…
Abstract Number: 1666 • ACR Convergence 2020
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
Laura Cannon¹, Anne Skelley-Caliendo², Aimee Hersh³ and Andrea Knight⁴, ¹Duke University, Durham, NC, ²Northwestern University, Chicago, IL, ³University of Utah and Primary Children's Hospital, Salt Lake City, ⁴Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: An estimated 15 to 20% of patients with systemic lupus erythematosus (SLE) have childhood-onset SLE (cSLE). Given the early onset of cSLE, patients often…
Abstract Number: 0111 • ACR Convergence 2020
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic
Amanda Stefl¹, Shikha Singla², Jessica Michaud¹, Kama Thomas², Lisa Rein² and Mary Ellen Csuka², ¹Froedtert Hospital, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
Abstract Number: 1698 • ACR Convergence 2020
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Ruhani Desai¹, Cassandra Calabrese², Neel Patel³ and Jessica Donato⁴, ¹Cleveland Clinic Foundation, DeLand, FL, ²Cleveland Clinic, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
Abstract Number: 0148 • ACR Convergence 2020
Perspectives on Treatment Burden for Methotrexate and TNF-inhibitors Among Psoriatic Arthritis and Rheumatoid Arthritis Patients: A Qualitative Study
Alexis Ogdie¹, Yomei Shaw², Michele Almonte³, Ervant Maksabedian⁴ and Kaleb Michaud⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc., LOS ANGELES, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Physicians often consider adverse events when choosing therapies for PsA and RA but may give less attention to other ways in which treatments affect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].